Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab

• Yesim Dargaud,
• Anne Lienhart,
• Maissaa Janbain,
• Sandra Le Quellec,
• Nathalie Enjolras,
• Claude Negrier

Affiliations

Yesim Dargaud

Unite d’Hemostase Clinique, Hopital Cardiologique Louis Pradel, Lyon, France;EA 4609-Hémostase et Cancer, UFR Laennec, Universite Claude Bernard Lyon I, France

Anne Lienhart

Unite d’Hemostase Clinique, Hopital Cardiologique Louis Pradel, Lyon, France

Maissaa Janbain

Tulane School of Medicine, Louisiana Center for Bleeding and Clotting Disorders, New Orleans, LA, USA

Sandra Le Quellec

Unite d’Hemostase Clinique, Hopital Cardiologique Louis Pradel, Lyon, France;EA 4609-Hémostase et Cancer, UFR Laennec, Universite Claude Bernard Lyon I, France

Nathalie Enjolras

EA 4609-Hémostase et Cancer, UFR Laennec, Universite Claude Bernard Lyon I, France

Claude Negrier

Unite d’Hemostase Clinique, Hopital Cardiologique Louis Pradel, Lyon, France;EA 4609-Hémostase et Cancer, UFR Laennec, Universite Claude Bernard Lyon I, France